Greenwich LifeSciences (NASDAQ:GLSI) Releases Quarterly Earnings Results, Beats Expectations By $0.06 EPS

Greenwich LifeSciences (NASDAQ:GLSI) posted its quarterly earnings data on Tuesday. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.06, FiscalAI reports.

Greenwich LifeSciences Stock Performance

Greenwich LifeSciences stock traded down $0.38 during midday trading on Thursday, reaching $16.55. The stock had a trading volume of 39,446 shares, compared to its average volume of 236,267. Greenwich LifeSciences has a 1-year low of $7.78 and a 1-year high of $34.10. The stock has a market capitalization of $242.88 million, a P/E ratio of -10.83 and a beta of 1.46. The firm’s fifty day simple moving average is $18.84 and its 200-day simple moving average is $23.44.

Insider Transactions at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 2,500 shares of Greenwich LifeSciences stock in a transaction dated Thursday, July 23rd. The stock was bought at an average cost of $13.14 per share, for a total transaction of $32,850.00. Following the purchase, the chief executive officer directly owned 5,606,602 shares in the company, valued at approximately $73,670,750.28. This represents a 0.04% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this link. In the last quarter, insiders have acquired 5,800 shares of company stock valued at $76,618. 51.47% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Greenwich LifeSciences

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. XTX Topco Ltd bought a new stake in Greenwich LifeSciences during the fourth quarter worth $217,000. Man Group plc bought a new stake in Greenwich LifeSciences in the 4th quarter valued at $590,000. Barclays PLC boosted its position in shares of Greenwich LifeSciences by 11.8% in the fourth quarter. Barclays PLC now owns 9,744 shares of the company’s stock valued at $205,000 after acquiring an additional 1,030 shares during the period. State Street Corp grew its position in shares of Greenwich LifeSciences by 19.3% during the 4th quarter. State Street Corp now owns 97,777 shares of the company’s stock worth $2,054,000 after purchasing an additional 15,831 shares in the last quarter. Finally, Wells Fargo & Company MN grew its position in Greenwich LifeSciences by 109.6% during the fourth quarter. Wells Fargo & Company MN now owns 7,845 shares of the company’s stock worth $165,000 after buying an additional 4,102 shares in the last quarter. Institutional investors own 4.16% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on GLSI. Wall Street Zen lowered Greenwich LifeSciences from a “hold” rating to a “sell” rating in a report on Saturday, June 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Greenwich LifeSciences in a report on Friday, May 15th. Finally, HC Wainwright lifted their price target on Greenwich LifeSciences from $50.00 to $69.00 and gave the company a “buy” rating in a report on Tuesday, July 21st. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Greenwich LifeSciences has a consensus rating of “Hold” and a consensus target price of $57.00.

Greenwich LifeSciences Company Profile

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.